granulomatosis polyangiitis gpa previously known wegeners granulomatosis nazi german physician friedrich wegener rare longterm systemic disorder involves formation granulomas inflammation blood vessels vasculitis autoimmune disease form vasculitis affects small mediumsize vessels many organs commonly affects upper respiratory tract lungs signs symptoms gpa highly varied reflect organs supplied affected blood vessels typical signs symptoms include nosebleeds stuffy nose crustiness nasal secretions inflammation uveal layer damage heart lungs kidneys fatal cause gpa unknown genetics found play role gpa though risk inheritance appears gpa treatment depends severity severe disease typically treated combination immunosuppressive medications rituximab cyclophosphamide highdose corticosteroids control symptoms disease azathioprine methotrexate rituximab keep disease plasma exchange also used severe cases damage lungs kidneys number new cases gpa year estimated new cases per million people gpa rare japanese africanamerican populations occurs often people northern european gpa estimated affect cases per people united states equally affects men initial signs highly variable diagnosis severely delayed due nonspecific nature symptoms general irritation inflammation nose first sign involvement upper respiratory tract nose sinuses seen nearly people typical signs symptoms nose sinus involvement include crusting around nose stuffiness nosebleeds runny nose saddlenose deformity due hole septum inflammation outer layers eye scleritis conjunctivitis common signs gpa eye involvement eyes common occurs slightly half people cause gpa unknown although microbes bacteria viruses well genetics implicated classic microscopic features gpa include inflammation blood vessels associated poorly formed granulomas necrosis many giant bacterial colonization staphylococcus aureus hypothesized initiating factor autoimmunity seen people several genes involved immune system including human leukocyte antigen genes may influence risk developing widely presumed antineutrophil cytoplasmic antibodies ancas responsible inflammation typical ancas gpa react proteinase enzyme prevalent neutrophil vitro studies found ancas activate neutrophils increase adherence endothelium induce degranulation damage endothelial cells theory phenomenon could cause extensive damage vessel wall particular granulomatosis polyangiitis usually suspected person unexplained symptoms long period time determination antineutrophil cytoplasmic antibodies ancas aid diagnosis positivity conclusive negative ancas sufficient reject diagnosis people gpa test positive cytoplasmicstaining ancas react enzyme proteinase canca neutrophils type white blood cell associated involvement ears nose throat common granulomatosis polyangiitis similar condition microscopic person signs kidney involvement cutaneous vasculitis biopsy obtained kidneys rare occasions thoracoscopic lung biopsy required histopathological examination biopsy show leukocytoclastic vasculitis necrotic changes granulomatous inflammation clumps typically arranged white blood cells microscopy granulomas main reason name granulomatosis polyangiitis although essential feature nevertheless necrotizing granulomas hallmark disease however many biopsies nonspecific provide little information diagnosis granulomatosis polyangiitis part larger group vasculitic syndromes called systemic vasculitides necrotizing vasculopathies feature autoimmune attack abnormal type circulating antibody termed ancas antineutrophil cytoplasmic antibodies small mediumsize blood vessels apart gpa category includes eosinophilic granulomatosis polyangiitis egpa microscopic although gpa affects small mediumsize formally classified one small vessel vasculitides chapel hill american college rheumatology accepted classification criteria gpa criteria intended diagnosis inclusion randomized controlled trials two positive criteria sensitivity specificity describing according chapel hill consensus conference chcc nomenclature systemic vasculitis establishing diagnosis gpa several investigators compared acr chapel hill american college rheumatology european alliance associations rheumatology updated classification criteria gpa treatment depends severity whether caused organ standard treatment severe gpa induce remission immunosuppressants rituximab cyclophosphamide combination highdose plasmapheresis sometimes recommended severe manifestations gpa diffuse alveolar hemorrhage rapidly progressive glomerulonephritis seen pulmonaryrenal use plasmapheresis gpa acute kidney failure renal vasculitis might reduce progression endstage kidney disease three oral intravenous cyclophosphamide effective induction gpa remission oral cyclophosphamide dose mgkgday standard treatment many years regimen resulted complete remission people gpa associated significant toxicities including infertility inflammation bleeding bladder bladder contrast administering pulsed doses intravenous cyclophosphamide equally effective inducing remission results lower cumulative dose decreases incidence abnormally low white blood cell counts however pulsed intravenous cyclophosphamide may associated higher risk gpa relapse compared oral due high frequency abnormally low white blood cell counts seen cyclophosphamide treatment pneumocystis jirovecii pneumonia common complication prophylaxis pathogen rituximab may substituted cyclophosphamide induce remission since similarly effective comparable side effect dose corticosteroids generally tapered decreased slowly course several months reduce risk another gpa flare person gpa successfully undergone induction gone remission treatment goal shifts maintenance remission preventing subsequent gpa flares less toxic immunosuppressing medications rituximab methotrexate azathioprine leflunomide mycophenolate mofetil tnf inhibitors etanercept appear ineffective recommended routine generalized nonorganthreatening disease remission achieved combination methotrexate corticosteroids steroid dose reduced remission achieved methotrexate used maintenance therapy treatment measures localised gpa nose sinuses includes nasal irrigation nasal corticosteroids antibiotics infection perforation nasal septum occurs saddle nose deformity surgical repair trimethoprimsulfamethoxazole proposed help prevent relapse though cochrane review confirm fewer relapses trimethoprimsulfamethoxazole modern treatments survival average survival five death usually resulted uremia respiratory revised fivefactor score associated mortality gpa based following criteria age greater years cardiac symptoms gastrointestinal involvement chronic kidney disease absence ears nose throat corticosteroids cyclophosphamide survival longterm complications common mainly chronic kidney failure hearing loss risk relapse increased people gpa test positive anca antibodies higher relapse risk microscopic today medication toxicity managed carefully longterm remissions possible affected individuals able lead relatively normal lives remain remission years incidence cases per million per exceedingly rare japan african scottish otolaryngologist peter mcbride first described condition bmj article entitled photographs case rapid destruction nose heinz karl ernst klinger born added information anatomical pathology early name disease pathergic disease still sometimes confused lethal midline granuloma lymphomatoid granulomatosis malignant full clinical picture first presented friedrich wegener german pathologist two reports leading eponymous name wegeners granulomatosis wegener granulomatosis english american college rheumatology acr american society nephrology asn european league rheumatism eular resolved change name granulomatosis polyangiitis given wegeners association nazi httpsenwikipediaorgwikigranulomatosiswithpolyangiitis